Don't Do Something!: Just Stand There.
About:
This article is published in Journal of the American College of Cardiology.The article was published on 2019-05-28 and is currently open access. It has received 0 citations till now. The article focuses on the topics: Balloon & Angioplasty.read more
References
More filters
Journal ArticleDOI
Risk of Death Following Application of Paclitaxel‐Coated Balloons and Stents in the Femoropopliteal Artery of the Leg: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Konstantinos Katsanos,Stavros Spiliopoulos,Panagiotis Kitrou,Miltiadis Krokidis,Dimitrios Karnabatidis +4 more
TL;DR: There is increased risk of death following application of paclitaxel‐coated balloons and stents in the femoropopliteal artery of the lower limbs.
Journal ArticleDOI
Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial.
Adnan Kastrati,Julinda Mehilli,Nicolas von Beckerath,Alban Dibra,Jörg Hausleiter,Jürgen Pache,Helmut Schühlen,Claus Schmitt,Josef Dirschinger,Albert Schömig +9 more
TL;DR: In patients with in-stent restenosis, a strategy based on sirolimus- or paclitaxel-eluting stents is superior to conventional balloon angioplasty for the prevention of recurrent restenotic.
Journal ArticleDOI
Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease
TL;DR: Among patients with symptomatic femoropopliteal peripheral artery disease, percutaneous transluminal angioplasty with a paclitaxel-coated balloon resulted in a rate of primary patency at 12 months that was higher than the rate with angioplated with a standard balloon.
Journal ArticleDOI
Paclitaxel-Eluting Stents Show Superiority to Balloon Angioplasty and Bare Metal Stents in Femoropopliteal Disease Twelve-Month Zilver PTX Randomized Study Results
Michael D. Dake,Gary M. Ansel,Michael R. Jaff,Takao Ohki,Richard R. Saxon,H. Bob Smouse,Thomas Zeller,Gary S. Roubin,Mark W. Burket,Yazan Khatib,Scott A. Snyder,Anthony Ragheb,J. King White,Lindsay S. Machan +13 more
TL;DR: Femoropopliteal peripheral artery disease treatment with the paclitaxel-eluting stent was associated with superior 12-month outcomes compared with PTA and provisional bare metal stent placement.
Journal ArticleDOI
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial
Michael D. Dake,Gary M. Ansel,Michael R. Jaff,Takao Ohki,Richard R. Saxon,H. Bob Smouse,Lindsay S. Machan,Scott A. Snyder,Erin E. O’Leary,Anthony Ragheb,Thomas Zeller +10 more
TL;DR: In this paper, a randomized controlled trial evaluated clinical durability of Zilver PTX, a paclitaxel-coated drug-eluting stent (DES), for femoropopliteal artery lesions.